Your rights

1. Screening

Based on an upfront agreed programme plan, your selected Programme is screened against those compounds that are available within the ESCulab Compound Collection. Any ’threshold active’ hits are then identified for further characterization and hit qualification.

All experimental work is performed by the public consortium partners of the ESCulab consortium, supported by IMI funding. Your input may include assay materials (DNA plasmids, proteins etc) and hands-on experience with the assay(s) for trouble-shooting.

The outcome of the Programme will be a ‘Qualified Hit List’ (QHL) of up to 50 compounds with associated biological data. Where meaningful, the QHL might also contain inactive structural analogues of threshold active hits, to provide a potential structure-activity relationship.

2. Access Rights

You will receive the access rights and 3-year exclusivity to progress the QHL results (subject to exceptions, e.g. in case of patenting and the EFPIA option process, see Obligations). In order to give you enough time to progress to a potentially patentable set of data, all threshold active compounds disclosed in your QHL are made unavailable to other screening programmes within the EU Lead Factory. During the ‘exclusivity period’ you are under no obligation to disseminate/publish screening results.

3. Exploitation

You are free to decide for your own Programme how results (in part or whole) will be advanced, for example by direct exploitation and/or research use. Please note that publication of results is subject to an option right for licensing granted to EFPIA Participants and the publication policy of the European Lead Factory as detailed under Obligations.